Turkey Tail Mushroom for Treating Post-Menopausal Women With HER2-Negative ER-Positive Breast Cancer Undergoing Surgery
Part of paid clinical trials in Scottsdale, Arizona.
- Sponsor
- Mayo Clinic
- Study ID
- NCT06450873
- Phase
- PHASE2
- Status
- Recruiting
Conditions
- Estrogen Receptor-Positive Breast Carcinoma
- HER2-Negative Breast Carcinoma
Eligibility Criteria
- Sex
- FEMALE
- Age
- 18 Years - N/A
- Healthy Volunteers
- Not accepted
Interventions
- Coriolus Versicolor Extract — DRUGDietary Supplement Given PO
- Questionnaire Administration — OTHERAncillary studies
Study Details
This phase II trial tests how well turkey tail mushroom (TTM) works in treating post-menopausal women with HER2-negative, estrogen receptor (ER)-positive breast cancer undergoing surgery. TTM is a common mushroom. In traditional Chinese medicine, it is used for enhancing function and removing toxins, as well as for cancer, hepatitis, and infections. There is previous evidence of significant tumor shrinkage occurring in the 2-month window between diagnosis and surgery in women who have taken TTM. Giving TTM may be effective in treating post-menopausal women with HER2-negative, ER-positive breast cancer undergoing surgery.
Key Dates
- Start date
- Oct 25, 2024
- Status verified
- Mar 2026
- Primary completion
- Dec 30, 2027
- Completion
- Apr 30, 2028
Study Design
- Enrollment
- 40 participants (estimated)
- Allocation
- NA
- Intervention model
- SINGLE_GROUP
- Primary purpose
- TREATMENT
Arms
- Experimental: Treatment (TTM)Patients receive TTM PO BID starting at the time of study registration and continuing up to the day prior to SOC surgery (up to 20-42 days) in the absence of disease progression or unacceptable toxicity.
Primary Outcome Measure
Change in Ki-67 [ Time Frame: Baseline; at the time of surgery ]
Central Contacts
- Clinical Trials Referral Office855-776-0015
- Cancer Center Clinical Trials507-293-6386
Locations (1)
| Facility | City | State | ZIP | Site coordinators |
|---|---|---|---|---|
| Mayo Clinic in Arizona | Scottsdale | Arizona | 85259 | Cancer Center Clinical Trials 507-293-6386 Brenda J. Ernst, MD (PRINCIPAL_INVESTIGATOR) |
Find similar trials in Scottsdale, AZ
By research site
Related Studies
- Adding an Immunotherapy Drug, MEDI4736 (Durvalumab), to the Usual Chemotherapy Treatment (Paclitaxel, Cyclophosphamide, and Doxorubicin) for Stage II-III Breast CancerPHASE3 · Recruiting · National Cancer Institute (NCI) · Birmingham, Alabama
- Mobile Health for Adherence in Breast Cancer PatientsRecruiting · ECOG-ACRIN Cancer Research Group · Fairbanks, Alaska
- Finding the Best Tamoxifen Dose for Breast Cancer Risk Reduction in Premenopausal Women, RENAISSANCE TrialPHASE2 · Recruiting · National Cancer Institute (NCI) · Tucson, Arizona
- Letrozole With and Without Simvastatin for the Treatment of Stage I-III Hormone Receptor Positive, HER2 Negative Breast CancerEARLY_PHASE1 · Recruiting · Emory University · Atlanta, Georgia